Article

Aggressive Cholesterol Lowering Therapy May Reverse Atherosclerosis

Intensive treatment to LDL-C reduces CIMT in patients with type 2 diabetes, according to a secondary analysis from the SANDS trial.

Intensive treatment to lower low-density lipoprotein cholesterol (LDL-C) reduces carotid intima-media thickness (CIMT) in patients with type 2 diabetes, according to a secondary analysis from the Stop Atherosclerosis in Native Diabetics Study (SANDS) trial.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Related Content
FDA Approves Tirzepatide for Obstructive Sleep Apnea in Obesity | Image Credit: US Food and Drug Administration
December 20th 2024

FDA Approves Tirzepatide for Obstructive Sleep Apnea in Obesity

Connor Iapoce
Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor
December 16th 2024

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial | Image Credit: Novo Nordisk
December 20th 2024

CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial

Connor Iapoce
Irl Hirsch, MD | Credit: University of Washington
December 12th 2024

Diabetes Dialogue: Celebrating 25 Years of CGM, with Irl Hirsch, MD

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
LIB Therapeutics Submits Lerodalcibep BLA Targeting Reduction in Elevated LDL-C | Image Credit: US Food and Drug Administration
December 19th 2024

LIB Therapeutics Submits BLA for Lerodalcibep Targeting Reductions in LDL-C

Connor Iapoce
Jörn M. Schattenberg, MD | Credit: LinkedIn
December 15th 2024

Study Highlights Real-World Mortality Rates, Factors Increasing Mortality Risk in MASH

Patrick Campbell
© 2024 MJH Life Sciences

All rights reserved.